TIDMHCM
Hutchison China Meditech Limited
28 March 2019
Press Release
Chi-Med Highlights Oral Presentations on Savolitinib Lung Cancer
Programs at AACR Annual Meeting
London: Thursday, March 28, 2019: Hutchison China MediTech
Limited ("Chi-Med") (AIM/Nasdaq: HCM) will share further data on
the savolitinib development programs in lung cancer at the American
Association of Cancer Research (AACR) Annual Meeting in Atlanta,
Georgia, USA, March 31 to April 3, 2019.
Preliminary efficacy and safety results will be presented from
the China Phase II study of savolitinib monotherapy in non-small
cell lung cancer ("NSCLC") patients with MET Exon 14 skipping
mutations who have failed prior systemic therapy, or are unable to
receive chemotherapy (abstract #CT031, clinicaltrials.gov
identifier NCT02897479).
In addition, several abstracts will be presented from the TATTON
Phase Ib/II trial of savolitinib in combination with Tagrisso(R)
(osimertinib) in patients with epidermal growth factor receptor
("EGFR") mutation-positive NSCLC and MET-amplification who have
progressed following treatment with an EGFR tyrosine kinase
inhibitor ("EGFR-TKI") (clinicaltrials.gov identifier NCT02143466).
One presentation will focus on patients who had progressed on a
first- or second-generation EGFR-TKI and had not previously
received a third-generation EGFR-TKI (abstract #CT032). Another
presentation will focus on patients whose disease further
progressed despite prior treatment with a third-generation EGFR-TKI
(abstract #CT033). These presentations are complemented by a poster
presentation on detection methods for identifying MET-driven
EGFR-TKI resistance in the TATTON trial (abstract #4897/20).
TATTON preliminary results were presented at the World
Conference on Lung Cancer (WCLC) in Yokohama, Japan, in October
2017.[1] The TATTON trial supports SAVANNAH, an ongoing Phase II
clinical trial exploring the combination of savolitinib and
Tagrisso(R) to overcome MET-driven EGFR-TKI resistance following
treatment with Tagrisso(R) (clinicaltrials.gov identifier
NCT03778229).
Further details of the presentations are as follows:
Session: Can the Challenge of NSCLC Resistance Be MET or Will We Not MEK It?
Session Type: Clinical Trials Plenary Session
Session # & Link: CTPL02
Date & Time: Sunday, March 31: 3:00 PM-5:15 PM
Location: Marcus Auditorium, Building A, Georgia World Congress Center
1(st) Presentation Preliminary efficacy and safety results of savolitinib treating patients with pulmonary
Title: sarcomatoid
carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14
skipping mutations
Lead Author: Shun Lu, Professor at Shanghai Chest Hospital, Jiao Tong University
Abstract # & Link: CT031 - abstract available after 3:00 PM EST on Friday, March 29, 2019
Time: 3:05 PM-3:30 PM
2(nd) Presentation TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with
Title: EGFR-mutant,
MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI)
Lead Author: Helena A. Yu, Medical Oncologist at Memorial Sloan Kettering Cancer Center
Abstract # & Link: CT032 - abstract only available at time of presentation
Time: 3:40 PM-3:55 PM
3(rd) Presentation TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) with
Title: EGFR-mutant,
MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor (TKI)
Lead Author: Lecia V. Sequist, Associate Professor of Medicine at Harvard Medical School and the Director
of the Center for Innovation in Early Cancer Detection at Massachusetts General Hospital
Abstract # & Link: CT033 - abstract only available at time of presentation
Time: 3:55 PM-4:15 PM
Session: Novel Strategies for Biomarker Identification and Use in Cancer 3
Poster Title: Detection of MET-mediated EGFR tyrosine kinase inhibitor (TKI) resistance in advanced non-small
cell lung cancer (NSCLC): biomarker analysis of the TATTON study
Lead Author: Ryan J. Hartmaier, AstraZeneca
Abstract # & Link: 4897 / 20 - abstract now available
Date & Time: April 3, 2019, 8:00 AM - 12:00 PM
Location: Section 19, Building B, Georgia World Congress Center
About Savolitinib
Savolitinib is a potential first-in-class inhibitor of c-MET, an
enzyme which has been shown to function abnormally in many types of
solid tumors. Chi-Med designed savolitinib to be a potent and
highly selective oral inhibitor, which, through chemical structure
modification, addresses human metabolite-related renal toxicity,
the primary issue that halted development of several other
selective c-MET inhibitors. In clinical studies to date, involving
over 900 patients, savolitinib has shown promising signs of
clinical efficacy in patients with c-MET gene alterations in
multiple tumor types with an acceptable safety profile. Chi-Med is
currently testing savolitinib in partnership with AstraZeneca in
Phase Ib/II studies, in multiple solid tumor indications, both as a
monotherapy and in combinations.
About Chi-Med
Chi-Med (AIM/Nasdaq: HCM) is an innovative biopharmaceutical
company which researches, develops, manufactures and markets
pharmaceutical products. Its Innovation Platform, Hutchison
MediPharma, has about 420 scientists and staff focusing on
discovering, developing and commercializing targeted therapeutics
and immunotherapies in oncology and autoimmune diseases. It has a
portfolio of eight cancer drug candidates currently in clinical
studies around the world. Chi-Med's Commercial Platform
manufactures, markets, and distributes prescription drugs and
consumer health products, covering an extensive network of
hospitals across China.
Dual-listed on the AIM market of the London Stock Exchange and
the Nasdaq Global Select Market, Chi-Med is headquartered in Hong
Kong and majority owned by the multinational conglomerate CK
Hutchison Holdings Limited (SEHK: 1). For more information, please
visit: www.chi-med.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the U.S. Private
Securities Litigation Reform Act of 1995. These forward-looking
statements reflect Chi-Med's current expectations regarding future
events, including its expectations for the clinical development of
savolitinib, plans to initiate clinical studies for savolitinib,
its expectations as to whether such studies would meet their
primary or secondary endpoints, and its expectations as to the
timing of the completion and the release of results from such
studies. Forward-looking statements involve risks and
uncertainties. Such risks and uncertainties include, among other
things, assumptions regarding enrollment rates, timing and
availability of subjects meeting a study's inclusion and exclusion
criteria, changes to clinical protocols or regulatory requirements,
unexpected adverse events or safety issues, the ability of drug
candidate savolitinib to meet the primary or secondary endpoint of
a study, to obtain regulatory approval in different jurisdictions
and to gain commercial acceptance after obtaining regulatory
approval, the potential market of savolitinib for a targeted
indication and the sufficiency of funding. In addition, as certain
studies rely on the use of Tagrisso(R) , Iressa(R) and Imfinzi(R)
as combination therapeutics with savolitinib, such risks and
uncertainties include assumptions regarding the safety, efficacy,
supply and continued regulatory approval of Tagrisso(R) , Iressa(R)
and Imfinzi(R) . Existing and prospective investors are cautioned
not to place undue reliance on these forward-looking statements,
which speak only as of the date hereof. For further discussion of
these and other risks, see Chi-Med's filings with the U.S.
Securities and Exchange Commission and on AIM. Chi-Med undertakes
no obligation to update or revise the information contained in this
press release, whether as a result of new information, future
events or circumstances or otherwise.
CONTACTS
Investor Enquiries
Mark Lee, Senior Vice President, Corporate Finance & Development +852 2121 8200
Annie Cheng, Vice President, Corporate Finance & Development +1 (973) 567 3786
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile)
david.dible@citigatedewerogerson.com
Xuan Yang, Solebury Trout +1 (415) 971 9412 (Mobile)
xyang@troutgroup.com
Media Enquiries
UK & Europe - Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile)
anthony.carlisle@cdrconsultancy.co.uk
Americas - Brad Miles, Solebury Trout +1 (917) 570 7340 (Mobile)
bmiles@troutgroup.com
Hong Kong & Asia ex-China - Joseph Chi Lo, Brunswick +852 9850 5033 (Mobile)
jlo@brunswickgroup.com
- Zhou Yi, Brunswick +852 9783 6894 (Mobile)
yzhou@brunswickgroup.com
Mainland China - Sam Shen, Edelman +86 136 7179 1029 (Mobile)
sam.shen@edelman.com
Nominated Advisor
Richard Gray / Atholl Tweedie, Panmure Gordon (UK) Limited +44 (20) 7886 2500
[1] Ahn M-J, et al. TATTON Phase Ib Expansion Cohort:
Osimertinib Plus Savolitinib for Patients with EGFR-mutant
MET-amplified NSCLC After Progression on Prior EGFR-TKI. Abstract
#8985. Presented at the World Lung Cancer Congress (WCLC) 2017,
Yokohama, Japan, 15-18 October 2017.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRADVLBLKXFBBBE
(END) Dow Jones Newswires
March 28, 2019 03:30 ET (07:30 GMT)
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hutchison China Meditech (LSE:0J7G)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024